aibioBioCryst Pharmaceuticals BCRX lawsuit news
Top story · Aug 5, 2026 · aibio.space
BioCryst sues Annora, Hetero and Camber in Delaware over generic ORLADEYO
BioCryst filed the patent suit on March 10, 2025 after Paragraph IV notices from Annora Pharma. The 10-Q says the case is in early stages and no estimate of loss is possible.
- Ticker
- BCRX
- Listing
- NASDAQ, United States
- Next date
- November 4, 2026
- Chief executive
- Charlie Gayer, President and Chief Executive Officer
Desk view · Opinion · Updated Oct 22, 2026
BioCryst is profitable now. The 2027 readout decides what comes next
BioCryst has turned into a profitable one-drug company that is spending its Orladeyo cash on navenibart and outside deals rather than its own labs. The near-term story is U.S. Orladeyo growth and the pellet launch; the long-term story is whether navenibart works in phase 3 in 2027 and whether management buys good assets.
Read the full desk viewaibio.space Investor Rank · Opinion
6/10 Neutral view
Profitable on Orladeyo but dependent on that one drug, carrying $400 million of term debt and waiting until 2027 for navenibart phase 3 data.
- Technology
- 2/2
- Odds
- 1/2
- Balance sheet
- 1/2
- Risk
- 1/2
- Momentum
- 1/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Proven commercial drug. Orladeyo is an approved oral kallikrein inhibitor with $158.2 million of Q2 sales; navenibart extends the same target to injections every three or six months.
- Odds
- Navenibart is in phase 3. Enrollment finished in June 2026 and top-line data are due in Q3 2027; rare disease phase 3 programs reach filing about 60% of the time.
- Balance sheet
- Profitable but levered. BioCryst held $354.0 million at June 30 and posted Q2 net income, while carrying $400 million of term debt due 2031.
- Main risk
- Single-product dependence. Orladeyo provides nearly all product revenue and faces a generic patent challenge and new HAE competitors.
- Watch next
- Pellet launch numbers. Q3 results on November 4 will be the first with pediatric pellet sales, and BCX17725 data are due by year end.
Top news on BioCryst
- Legal
BioCryst sues Annora, Hetero and Camber in Delaware over generic ORLADEYO
BioCryst filed the patent suit on March 10, 2025 after Paragraph IV notices from Annora Pharma. The 10-Q says the case is in early stages and no estimate of loss is possible.
- Financings
BioCryst to close Birmingham discovery center, cuts 2026 spending outlook
The HAE drugmaker will stop internal drug discovery and look outside for new programs. A later 8-K/A put severance at $6.2 million to $7.5 million, and a state WARN notice listed 47 jobs at the site.
Questions investors ask
What is aibio.space's Investor Rank for BioCryst Pharmaceuticals?
6 out of 10, our neutral view. Profitable on Orladeyo but dependent on that one drug, carrying $400 million of term debt and waiting until 2027 for navenibart phase 3 data. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
What does BioCryst Pharmaceuticals sell?
BioCryst sells Orladeyo (berotralstat), an oral once-daily pill that prevents hereditary angioedema attacks, plus Rapivab for influenza. Orladeyo had net revenue of $158.2 million in the second quarter of 2026. Source
When will BioCryst report navenibart phase 3 results?
BioCryst expects top-line ALPHA-ORBIT results for both the three-month and six-month doses in the third quarter of 2027. Enrollment finished in June 2026. Source
Who is the CEO of BioCryst?
Charlie Gayer is president and chief executive officer of BioCryst. He was quoted in that role in the company's August 5, 2026 second-quarter results. Source
How much cash and debt does BioCryst have?
BioCryst had $354.0 million in cash, cash equivalents, restricted cash and investments at June 30, 2026. It owed $400 million under a Blackstone term loan that matures in January 2031. Source
Is there a generic challenge to Orladeyo?
Yes. Annora Pharma filed an ANDA challenging four Orladeyo patents that expire in May 2040, and BioCryst sued Annora and Hetero in Delaware. Six other Orange Book patents expiring in 2035 are not challenged. Source
What is the latest BioCryst Pharmaceuticals (BCRX) stock news?
Our latest story on BioCryst Pharmaceuticals, dated Aug 5, 2026: "BioCryst sues Annora, Hetero and Camber in Delaware over generic ORLADEYO". BioCryst filed the patent suit on March 10, 2025 after Paragraph IV notices from Annora Pharma. The 10-Q says the case is in early stages and no estimate of loss is possible. Source
What is BioCryst Pharmaceuticals's latest stock offering or financing news?
Our latest financing story, dated Jun 29, 2026: "BioCryst to close Birmingham discovery center, cuts 2026 spending outlook". The HAE drugmaker will stop internal drug discovery and look outside for new programs. A later 8-K/A put severance at $6.2 million to $7.5 million, and a state WARN notice listed 47 jobs at the site. Source
Is BioCryst Pharmaceuticals facing a lawsuit?
Our latest legal story, dated Aug 5, 2026: "BioCryst sues Annora, Hetero and Camber in Delaware over generic ORLADEYO". BioCryst filed the patent suit on March 10, 2025 after Paragraph IV notices from Annora Pharma. The 10-Q says the case is in early stages and no estimate of loss is possible. Claims in lawsuits are allegations until a court rules. Source
What is BioCryst Pharmaceuticals's market cap?
We do not publish live share prices. In its annual report, BioCryst Pharmaceuticals, Inc. put the market value of shares held by non-affiliates (public float) at $1.86 billion as of Jun 30, 2025. Source
Is BioCryst Pharmaceuticals a smaller reporting company?
SEC records list BioCryst Pharmaceuticals, Inc.'s filer category as: Large accelerated filer. Source
Where is BioCryst Pharmaceuticals headquartered?
SEC records list its business address as 4505 EMPEROR BOULEVARD, DURHAM, NC, 27703. Source
When does BioCryst Pharmaceuticals's fiscal year end?
BioCryst Pharmaceuticals, Inc.'s fiscal year ends on December 31, per SEC records. Source
What did BioCryst Pharmaceuticals last file with the SEC?
Its most recent filing in our record is a 10-Q filed 2026-08-05. All of its filings are on SEC EDGAR. Source
What industry is BioCryst Pharmaceuticals in?
Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source
Legal and investor matters
- Other
BioCryst to close discovery center and end internal discovery programs
On 2026-06-25 the board of BioCryst Pharmaceuticals approved a plan to discontinue its internal discovery programs and close its Discovery Center of Excellence in Birmingham, Alabama. The company said implementation should be substantially complete by the end of 2026. It said it could not yet estimate the total cost of the plan and would file an amendment to its Form 8-K once it could.
- Financing
BioCryst borrows $400 million under Blackstone term loan
On 2026-01-23 BioCryst Pharmaceuticals entered into a loan agreement with Blackstone Alternative Credit Advisors and Blackstone Life Sciences Advisors, with Wilmington Trust as agent. The agreement provided initial term loans of $400 million, which were funded on the closing date. BioCryst disclosed the loan in the same Form 8-K that reported the completion of its Astria Therapeutics acquisition.
- Other
Antitrust waiting period ends early for BioCryst's Astria deal
BioCryst Pharmaceuticals announced on 2025-12-03 that the Hart-Scott-Rodino waiting period for its pending acquisition of Astria Therapeutics had been terminated early. The company's later 10-Q says the acquisition closed on 2026-01-23, with each Astria share converted into 0.59 of a BioCryst share and $8.55 in cash.
- Other
BioCryst agrees to acquire Astria Therapeutics in stock and cash deal
On 2025-10-14 BioCryst Pharmaceuticals, Axel Merger Sub and Astria Therapeutics signed an agreement and plan of merger. Under its terms each Astria common share would convert into 0.59 of a BioCryst share plus $8.55 in cash, subject to adjustments. BioCryst's 10-Q filed 2026-08-05 states that the merger closed on 2026-01-23 and that Astria is now a wholly owned subsidiary.
- Governance
BioCryst CEO Jon Stonehouse to retire; Charlie Gayer named successor
On 2025-07-25 BioCryst Pharmaceuticals CEO Jon Stonehouse told the board he would retire effective 2025-12-31. On 2025-07-27 the board appointed Charlie Gayer as president effective 2025-08-01 and as chief executive officer effective 2026-01-01. The company disclosed the changes in a Form 8-K.
- Litigation
BioCryst sues Annora and Hetero over generic ORLADEYO filing
On 2025-03-10 BioCryst Pharmaceuticals sued Annora Pharma, Hetero Labs, Hetero USA and Camber Pharmaceuticals in the U.S. District Court for the District of Delaware. The suit asserts infringement of ORLADEYO patents expiring in May 2040, after Annora filed an abbreviated new drug application and sent Paragraph IV notices in January 2025 and January 2026. BioCryst says the case is at an early stage and it cannot estimate any loss.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| Orladeyo (berotralstat) capsules and oral pellets | Hereditary angioedema prophylaxis, ages 2 and older | Marketed; pediatric pellets began shipping the week of August 3, 2026 Source |
| Navenibart | Hereditary angioedema prophylaxis (every 3 or 6 months) | Phase 3 (ALPHA-ORBIT), enrollment complete June 2026 Source |
| BCX17725 (KLK5 inhibitor) | Netherton syndrome | Phase 1, part 4 dosing up to 12 patients Source |
| Rapivab (peramivir injection) | Influenza | Marketed Source |
Stock chart
SEC filings and registration
- SEC name
- Biocryst Pharmaceuticals Inc
- CIK
- 882796
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- BCRX (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 4505 EMPEROR BOULEVARD, DURHAM, NC, 27703
- Phone
- 919-859-1302
- Shares outstanding
- 255,535,105 as of 2026-07-31 (10-Q filed 2026-08-05)
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction